Krystal Biotech (KRYS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.79
- Estimate
- $1.91
- Surprise
- -6.5%
- Revenue (period 2026-06-30)
- $119.2M
- Score today
- 6.0/10
Revenue source: xbrl.
How the report landed
Krystal Biotech (KRYS) missed the $1.91 estimate with adjusted EPS of $1.79 — a clear 6.5% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates KRYS Buy (Wait) at 6.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -6.5% surprise compares with a +8.8% four-quarter average. Next scheduled report: 2027-02-16.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: VYJUVEK
- Expensive valuation
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $305.03
- Entry target
- $287.81
- Price target
- $342.39
- Stop
- $272.96
- Upside to target
- +12.2%
- Reward-to-risk
- 1.5:1
The stock trades at 41.4× trailing but 33.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
KRYS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.04B
- P/E (fwd)
- 33.4
- P/E (ttm)
- 41.4
- 52-week range
- $192.52–$382.54
- Off 52-week high
- 20.3%
- RSI (14)
- 38
- Volume vs avg
- 1.88×
- Score today
- 6.0/10